CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ('HBM' or the 'Company'; ...

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

Sensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial data from its Phase 1/2 study.

BioNTech's BNT327 shows promising survival data in lung cancer trial, with 72.7% of patients surviving one year, outperforming benchmarks set by Keytruda and Tecentriq.

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses SAFEbody technology utilized to create masked T ...

LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory ...

White T-shirts get a lot of attention, but let’s not forget their equally versatile counterpart: the exceedingly wearable, deceptively simple black T-shirt. It’s a staple you can wear to work ...

TNFR2 agonism has been shown to potentiate Treg function as well as maintenance ... small-cell lung cancer who do not respond to anti-PD-1 therapy. And we continue to work with Merck KGaA to ...

A team of scientists and regulatory experts will now begin work on the two-year programme, collaborating with academic bodies, the CCP industry and trade organisations. Their aim is to gather rigorous ...